ロード中...

Targeting DNA damage repair in small cell lung cancer and the biomarker landscape

Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 14% of all lung cancer diagnoses. Despite decades of active research, treatment options for SCLC are limited and resistance to the few Food and Drug Administration (FDA) approved therapies develops rapidly. With no approved...

詳細記述

保存先:
書誌詳細
出版年:Transl Lung Cancer Res
主要な著者: Sen, Triparna, Gay, Carl M., Byers, Lauren Averett
フォーマット: Artigo
言語:Inglês
出版事項: AME Publishing Company 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5835589/
https://ncbi.nlm.nih.gov/pubmed/29535912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.02.03
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!